How to Improve the Safe and Effective Use of Doxorubicin in Children with Cancer

Clin Pharmacokinet. 2015 Nov;54(11):1091-3. doi: 10.1007/s40262-015-0300-4.

Author

John N van den Anker^{1

2}

Affiliations

¹ Division of Pediatric Clinical Pharmacology, Children's National Health System, 111 Michigan Ave, NW, Washington, DC, 20010, USA. jvandena@cnmc.org.
² Department of Paediatric Pharmacology, University Children's Hospital Basel, Basel, Switzerland. jvandena@cnmc.org.

PMID: 26123706
DOI: 10.1007/s40262-015-0300-4

No abstract available

MeSH terms

Adolescent
Age Factors
Antibiotics, Antineoplastic / administration & dosage*
Antibiotics, Antineoplastic / adverse effects
Antibiotics, Antineoplastic / pharmacokinetics
Cardiotoxicity / etiology
Child
Child, Preschool
Doxorubicin / administration & dosage*
Doxorubicin / adverse effects
Doxorubicin / pharmacokinetics
Humans
Neoplasms / drug therapy*
Neoplasms / genetics
Neoplasms / metabolism

Substances

Antibiotics, Antineoplastic
Doxorubicin